Life Sciences

Supporting ambition for healthcare innovation

  • Sector expertise that seeks out the right financial services to meet our clients' growth needs
  • Knowledgeable, proactive and approachable team
  • Strong track record of raising capital and M&A advisory in public and private markets
  • One of the leading brokers and advisers in the public and AIM life sciences sector

We operate across the Life Science spectrum that includes therapeutic pharmaceuticals, biotechnology, medical devices and diagnostics. These distinct categories are drawn together by the incontrovertible truth that people are living longer, and need to lead healthier lives, with a better quality of life.

We have a breadth of experience in providing strategic advice to a range of companies - from earlier stage growth businesses, to privately backed scale-ups, to established, profitable PLC enterprises. We work with entrepreneurs, business founders and owners, Private Equity owners, PLC boards, and management teams alike.

We know that there is considerable innovation and opportunity in the Life Sciences sector - ambitious companies that want to grow through raising capital in different markets and we want to help them achieve their potential.

We recognise that growth companies can be nimbler when it comes to developing innovative technologies and products to sustain their expansion, and those services and capabilities can be provided to larger, more established players. Our research, financial strategists and sales specialists draw on their collective experience to support companies throughout their growth, helping to shape the way for a healthier future. 

Our services

  • IPO
  • M&A sale
  • Equity raise – private and public markets
  • Debt raise – private and public markets
  • Strategic options and exit review
  • NOMAD, Broker, Sponsor and PLC advisory

Latest Transactions

Ambition Delivered

Destiny Pharma Plc

Destiny Pharma Plc

Sector: Life Sciences
Up to £7m Fundraise
March 2022

Omega Diagnostics

Omega Diagnostics Group Plc

Sector: Life Sciences
£5m Placing with Open Offer up to £2m
February 2022

genedrive Plc technology

genedrive Plc

Sector: Life Sciences
£10.5m Placing and Open Offer
September 2021

Our Life Sciences Sector Transactions
finnCap Life Sciences Research

Why 2022 will be a record year for cell and gene therapy

Download the latest Life Sciences Insights, which heralds the encouraging new era of innovative technologies within the life sciences sector with long-term benefits and curative potential, Cell and Gene Therapy (CGT).

Download the report
finnCap Life Sciences Research

Life Sciences Research

finnCap operates an ‘access-for-all’ approach for corporate research into the Life Sciences sector, approved by the FCA and paid for by finnCap’s corporate clients.

Register for the Research Portal
Inside The Deal Event banner

VIDEO EVENT: Is tech the shot in the arm that healthcare needs?

In May 2021, Business Leader Magazine teamed up with finnCap Group to go ‘Inside the Deal’, a virtual event that dived into the topic of accelerating digital transformation across the healthcare sector.

Watch the event in full
finnCap report into HealthTech

HealthTech Report

Accompanying our event is this report from our expert analysts in the healthcare and life sciences sector, looking at digital transformation in healthcare - the HealthTech sector.

Download the report here

Get in touch

Geoff Nash

Director, Corporate Finance

Geoff Nash

Full bio
Mark Brewer

Director, Research

Mark Brewer

Full bio